Prevalence of cholinesterase inhibitors in subjects with dementia in Europe
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Purpose: To evaluate the prevalence of cholinesterase inhibitor (ChI) treatment in subjects with dementia in European countries. Methods: We studied the prevalence of treatment in subjects with dementia among European countries in 2004 (Belgium, France, Germany, Italy, the Netherlands, Poland, Portugal, Spain and the United Kingdom) by using estimates of prevalence of dementia and of ChI treatments according to sales and reimbursement data. Results: In 2004, estimated prevalence of ChI use among subjects with dementia ranged from 3.0% in the Netherlands to 20.3% in France. It was 17.5% in Spain, 6.7% in the UK and 5.9% in Italy. Donepezil was used by more than 60% of patients using a single ChI and represented almost 50% of reimbursements for patients that had used at least two different ChIs during the year. Galantamine and rivastigmine were respectively used by 22 and 18% of subjects using a single drug and 27 and 23% of reimbursements for patients that had used at least two different ChIs. Nevertheless, different patterns of use were found for individual countries. Conclusions: Prevalence of treatment by ChIs among subjects with dementia remains weak and varies greatly across Europe. Differences in reimbursement rates and health policies could partly explain these variations, as ChIs could have failed to convince health authorities because the outcomes considered for trials are not used by clinicians in their everyday practice. If donepezil was highly predominant across countries, variations in rivastigmine and galantamine importance could reflect local market specificities. Copyright © 2008 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H.-P., & van den Bussche, H. (2005) · BMJ · doi:10.1136/bmj.331.7512.321 · Cited by 522
Inequalities in dementia care across Europe: key findings of the Facing Dementia Survey
Bond, J., Stave, C., Sganga, A., Vincenzino, O., O'connell, B., & Stanley, R. L. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-504x.2005.00480.x · Cited by 185
Rimmer, E., Wojciechowska, M., Stave, C., Sganga, A., & O'Connell, B. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-504x.2005.00482.x · Cited by 88
Cited by
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Knowledge about Alzheimer's disease in the Brazilian population
Amado, D. K., & Brucki, S. M. D. (2018) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20180106 · Cited by 68
Padovani, A., Falato, S., & Pegoraro, V. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2182530 · Cited by 9
Metadata
- Authors
- Pariente, A., Helmer, C., Merliere, Y., Moore, N., Fourrier‐Réglat, A., & Dartigues, J.
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2008-05-29
- Volume
- 17
- Issue
- 7
- Pages
- 655-660
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W1975048681
- Cited by
- 42
- References
- 3
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.